[go: up one dir, main page]

CA2446582A1 - Reactifs et procedes destines a moduler des interactions induites par dkk - Google Patents

Reactifs et procedes destines a moduler des interactions induites par dkk Download PDF

Info

Publication number
CA2446582A1
CA2446582A1 CA002446582A CA2446582A CA2446582A1 CA 2446582 A1 CA2446582 A1 CA 2446582A1 CA 002446582 A CA002446582 A CA 002446582A CA 2446582 A CA2446582 A CA 2446582A CA 2446582 A1 CA2446582 A1 CA 2446582A1
Authority
CA
Canada
Prior art keywords
dkk
hbm
protein
lrp5
lrp6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446582A
Other languages
English (en)
Inventor
Kristina Allen
Anthony Anisowicz
Bheem M. Bhat
Veronique Damagnez
John Allen Robinson
Paul J. Yaworsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Oscient Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446582A1 publication Critical patent/CA2446582A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)

Abstract

L'invention concerne des réactifs, des composés, des compositions et des procédés relatifs à de nouvelles interactions du domaine extracellulaire de LRP5, HBM (un variant de LRP5), et/ou LRP6 avec Dkk, comprenant Dkk-1. Les divers acides nucléiques, polypeptides, anticorps, procédés de dosage, procédés de diagnostic, et procédés de traitement de l'invention sont afférents à ou ont un impact sur Dkk, LRP5, LRP6, HBM, et la signalisation Wnt. Dkk, LRP5, LRP6, HBM, et Wnt sont impliqués dans la signalisation osseuse et cellulaire adipeuse. Ainsi, l'invention concerne des réactifs et des procédés destinés à moduler les niveaux adipeux et/ou la masse osseuse et est utile dans le traitement et le diagnostic de niveaux adipeux anormaux et de troubles de la masse osseuse, tels que l'ostéoporose.
CA002446582A 2001-05-17 2002-05-17 Reactifs et procedes destines a moduler des interactions induites par dkk Abandoned CA2446582A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29131101P 2001-05-17 2001-05-17
US60/291,311 2001-05-17
US35305802P 2002-02-01 2002-02-01
US60/353,058 2002-02-01
US36129302P 2002-03-04 2002-03-04
US60/361,293 2002-03-04
PCT/US2002/015982 WO2002092015A2 (fr) 2001-05-17 2002-05-17 Reactifs et procedes destines a moduler des interactions induites par dkk

Publications (1)

Publication Number Publication Date
CA2446582A1 true CA2446582A1 (fr) 2002-11-21

Family

ID=27404041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446582A Abandoned CA2446582A1 (fr) 2001-05-17 2002-05-17 Reactifs et procedes destines a moduler des interactions induites par dkk

Country Status (7)

Country Link
EP (1) EP1395285A4 (fr)
JP (2) JP2005512508A (fr)
AU (1) AU2002342734B2 (fr)
BR (1) BR0209836A (fr)
CA (1) CA2446582A1 (fr)
IL (1) IL158750A0 (fr)
WO (1) WO2002092015A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107760686A (zh) * 2016-08-23 2018-03-06 上海伯豪医学检验所有限公司 Dkk‑1蛋白的核酸适配体及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235524D1 (de) 2002-04-17 2010-04-15 Deutsches Krebsforsch Verfahren zum Screening einer Substanz zur Modulierung der wnt -Signalkaskade.
ES2362681T3 (es) * 2002-12-05 2011-07-11 The Board Of Trustees Of The University Of Arkansas Determinantes moleculares de la osteopatía por mieloma y uso de los mismos.
US8124087B2 (en) 2002-12-05 2012-02-28 Board Of Trustees Of The University Of Arkansas Methods of controlling bone loss by inhibiting DKK1
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
EP1636385A4 (fr) * 2003-06-24 2010-06-02 Mirus Bio Corp Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
WO2005049797A2 (fr) 2003-11-17 2005-06-02 Merck & Co., Inc. Proteine dickkopf-4 de macaque de buffon, nucleotides codant pour ladite proteine, et utilisations de cette proteine
US7622553B2 (en) 2003-11-17 2009-11-24 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
WO2006015497A1 (fr) * 2004-08-13 2006-02-16 Val-Chum, S.E.C. Procedes d'utilisation d'une proteine dkk1, de polypeptides immunogenes de ladite proteine, d'acides nucleiques codant la proteine dkk1 ou des polypeptides, ou de ligands de ladite proteine, pour detecter des tumeurs et pour eliciter une reponse immunitaire contre des tumeurs
EP2121755A1 (fr) * 2007-02-08 2009-11-25 Merck & Co., Inc. Anticorps spécifiques de dkk-1
EP2567709B1 (fr) * 2007-11-02 2017-12-27 Novartis AG Molécules et procédés de modulation de la protéine 6 liée à un récepteur de lipoprotéine à faible densité (LRP6)
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2427490A1 (fr) * 2009-05-07 2012-03-14 Novartis AG Compositions et procédés d'utilisation pour la liaison de molécules à dickkopf-1 ou dickkopf-4 ou les deux
SA110310369B1 (ar) * 2009-05-12 2014-09-02 Pfizer أجسام مضادة تخص dkk-1 واستخداماتها
AU2011217964B2 (en) 2010-02-19 2016-07-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
EP3600418A4 (fr) * 2017-03-24 2021-01-13 Yale University Inhibition de la protéine 5 liée au récepteur de lipoprotéine de faible densité, qui supprime la formation de tumeur
KR102717656B1 (ko) 2017-05-31 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046743A1 (fr) * 1997-04-15 1998-10-22 The Wellcome Trust Limited As Trustee To The Wellcome Trust Nouveau recepteur de ldl
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
IL152654A0 (en) * 2000-05-26 2003-06-24 Genome Therapeutics Corp Regulating lipid levels via the zmaxi or hbm gene
MXPA03007327A (es) * 2001-02-16 2005-02-14 Genentech Inc Tratamiento que involucra la proteina dickkopf-1 o antagonistas de la misma.
WO2002092000A2 (fr) * 2001-05-11 2002-11-21 Genome Therapeutics Corporation Variantes du hbm modulant les niveaux de masse osseuse et de lipides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107760686A (zh) * 2016-08-23 2018-03-06 上海伯豪医学检验所有限公司 Dkk‑1蛋白的核酸适配体及其应用
CN107760686B (zh) * 2016-08-23 2021-04-16 上海伯豪医学检验所有限公司 Dkk-1蛋白的核酸适配体及其应用

Also Published As

Publication number Publication date
IL158750A0 (en) 2004-05-12
AU2002342734B2 (en) 2007-07-26
WO2002092015A2 (fr) 2002-11-21
WO2002092015A3 (fr) 2003-10-23
EP1395285A4 (fr) 2005-06-01
BR0209836A (pt) 2004-12-07
JP2005512508A (ja) 2005-05-12
EP1395285A2 (fr) 2004-03-10
JP2009142274A (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
US7700101B2 (en) Reagents and method for modulating Dkk-mediated interactions
AU2002342734B2 (en) Reagents and methods for modulating Dkk-mediated interactions
AU2002342734A1 (en) Reagents and methods for modulating Dkk-mediated interactions
KR100603683B1 (ko) 활막세포 단백질
US7416849B2 (en) HBM variants that modulate bone mass and lipid levels
WO2002006483A1 (fr) Nouveau peptide actif sur le plan physiologique et utilisation associee
EP2419133A1 (fr) Inhibition de la rspondine-3 dans des troubles osseux
US20090226463A1 (en) Novel method of modulating bone-related activity
US8444975B2 (en) Method for inhibiting bone resorption
KR20070084498A (ko) Ｔｏｒｃ 폴리뉴클레오티드 및 폴리펩티드, 및 사용 방법
EP2091556B1 (fr) Modèle animal non-humain pour des maladies metaboliques comprenant une mutation dans le gène sreb2/gpr85
US20070275872A1 (en) Peptides with Anti-Obesity Activity and Other Related Uses
Bennett et al. Odor-evoked gene regulation and visualization in olfactory receptor neurons
JP2018528213A (ja) 新規なｉｇｆｒ様レセプター及びその使用
JP2002345468A (ja) 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ
JP2003526369A (ja) 新規ポリヌクレオチドおよび同一物をコードする核酸
US20070092527A1 (en) Proton-sensing g-protein coupled receptors and dna sequences thereof
US7414109B2 (en) FIAT nucleic acids and proteins and uses thereof
US20050283842A1 (en) Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
Bassi A multidisciplinary approach to characterize the role of prokineticin receptor 2 (PROKR2) in Congenital Hypogonadotropic Hypogonadism (CHH)
JP2003116582A (ja) 新規生理活性ペプチドおよびその用途
Panda Role of tuberoinfundibular peptide 39 (TIP 39)/parathyroid hormone 2 receptor (PTH2R) signalling in the control of endochondral bone formation
Guo Developmental regulation of lipid-droplet transport in Drosophila

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued